ArticleBlood cancer journal2025

Debulking strategy prior to anti-BCMA/CD3 bispecific antibodies in extramedullary and/or high tumor burden RRMM: a retrospective cohort study.

Thomas Chalopin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.